1. Home > Latest Topics >

Question 20: Cost-effectiveness data for levofloxacin in CAP

20 June, 2018

question_20_9


LATEST TOPICS

Managing Infectious Diseases in Emergency Medicine: A Specialist’s Approach
10 April, 2024
Advancing standardised diagnosis and treatment of acute infectious disease: Insights from an expert in theory–technique integration
08 April, 2024
Managing severe infections: Practical approaches for antibiotic use, including combination therapy
05 March, 2024
Updating Traditional Approaches: Expert Insights on Addressing Urinary Tract Infections
26 February, 2024
Antibiotic resistance may be driven by diverse factors, including extreme climatic events
14 February, 2024

RELATED ARTICLES

Changes and Updates in the New ATS/IDSA 2019 CAP Guidelines
06 May, 2021
Community-acquired pneumonia: Insights into the current challenges and the role of levofloxacin
29 January, 2024
Community-acquired pneumonia: Insights into macrolide resistance and a review of levofloxacin use
05 July, 2021
Optimising the management of patients with community-acquired pneumonia and comorbidities with levofloxacin
05 December, 2022
Innovator versus Generic Antibiotics: Clinical Effectiveness in Pneumonia
23 October, 2023